Jaap Goudsmit

Active 1980–2025

184
Papers
35,263
Citations
112
h-index
180
i10-index

Citations

Citations per year for Jaap Goudsmit1981: 1 citations1983: 6 citations1984: 2 citations1986: 17 citations1987: 58 citations1988: 81 citations1989: 97 citations1990: 94 citations1991: 121 citations1992: 187 citations1993: 190 citations1994: 208 citations1995: 175 citations1996: 165 citations1997: 241 citations1998: 294 citations1999: 261 citations2000: 221 citations2001: 245 citations2002: 191 citations2003: 209 citations2004: 192 citations2005: 259 citations2006: 198 citations2007: 201 citations2008: 231 citations2009: 264 citations2010: 266 citations2011: 299 citations2012: 296 citations2013: 339 citations2014: 268 citations2015: 196 citations2016: 201 citations2017: 175 citations2018: 155 citations2019: 498 citations2020: 889 citations2021: 732 citations2022: 508 citations2023: 295 citations2024: 456 citations2025: 230 citations2026: 9 citations1982: no citations, so this year is not shown1985: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 3,972 citing papers, 37.8% of this breakdownUnited Kingdom: 838 citing papers, 8% of this breakdownNetherlands: 594 citing papers, 5.7% of this breakdownChina: 488 citing papers, 4.6% of this breakdownGermany: 415 citing papers, 3.9% of this breakdownFrance: 380 citing papers, 3.6% of this breakdownCanada: 352 citing papers, 3.4% of this breakdownItaly: 294 citing papers, 2.8% of this breakdownAustralia: 267 citing papers, 2.5% of this breakdownSwitzerland: 237 citing papers, 2.3% of this breakdownSpain: 186 citing papers, 1.8% of this breakdownJapan: 186 citing papers, 1.8% of this breakdown
0%37.8%Other 21.8%

Fields

  • Medicine49.2%
  • Immunology and Microbiology32.9%
  • Biochemistry, Genetics and Molecular Biology12.4%
  • Agricultural and Biological Sciences1.3%
  • Environmental Science0.7%
  • Neuroscience0.7%
  • Other2.8%

Topics

  • HIV Research and Treatment11.8%
  • HIV/AIDS drug development and treatment5.3%
  • HIV/AIDS Research and Interventions4.6%
  • Immune Cell Function and Interaction4.4%
  • SARS-CoV-2 and COVID-19 Research4.1%
  • Influenza Virus Research Studies3.8%
  • Other66%

Coauthors

All papers

Open in search
  1. Twenty-seven-year time trends in dementia incidence in Europe and the United States

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Kevin McRae‐McKee, Osorio Meirelles, Thomas H. Mosley, Matthew P. Pase, Bruce M. Psaty, Claudia L. Satizábal, Sudha Seshadri, Ingmar Skoog, Blossom C.M. Stephan, Hanna Wetterberg, Mei Mei Wong, Anna Zettergren, Albert Hofman - Neurology 2020 cited by 476

  2. Highly Conserved Protective Epitopes on Influenza B Viruses

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , - Science 2012 cited by 917

  3. Plasma tau, neurofilament light chain and amyloid-β levels and risk of dementia; a population-based cohort study

    Authors: , , , , , , , , , , , , , , , , - Brain 2020 cited by 339

  4. Antibody Recognition of a Highly Conserved Influenza Virus Epitope

    Authors: , , , , , , , - Science 2009 cited by 1,373

  5. A Highly Conserved Neutralizing Epitope on Group 2 Influenza A Viruses

    Authors: , , , , , , , , , , , , , , , , , , , - Science 2011 cited by 867

  6. A stable trimeric influenza hemagglutinin stem as a broadly protective immunogen

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Science 2015 cited by 632

  7. Heterosubtypic Neutralizing Monoclonal Antibodies Cross-Protective against H5N1 and H1N1 Recovered from Human IgM+ Memory B Cells

    Authors: , , , , , , , , , , , , , , , , - PLoS ONE 2008 cited by 751

  8. Human Monoclonal Antibody Combination against SARS Coronavirus: Synergy and Coverage of Escape Mutants

    Authors: , , , , , , , , , , , , , , , - PLoS Medicine 2006 cited by 745

  9. Biological age in healthy elderly predicts aging-related diseases including dementia

    Authors: , , , , , , , - Scientific Reports 2021 cited by 108

  10. C-Type Lectin-Like Molecule-1

    Authors: , , , , , , , , , , , , , , , , , - Cancer Research 2004 cited by 245

  11. Potent peptidic fusion inhibitors of influenza virus

    Authors: , , , , , , , , , , , , , , , - Science 2017 cited by 166

  12. A small-molecule fusion inhibitor of influenza virus is orally active in mice

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jaap Goudsmit, Ian A. Wilson - Science 2019 cited by 146

  13. Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity

    Authors: , , , , , , , , , , , , , , , , , , - Nature 2006 cited by 489

  14. Comparative Seroprevalence and Immunogenicity of Six Rare Serotype Recombinant Adenovirus Vaccine Vectors from Subgroups B and D

    Authors: , , , , , , , , , , , , , , , - Journal of Virology 2007 cited by 516

  15. Neutralizing Antibodies to Adenovirus Serotype 5 Vaccine Vectors Are Directed Primarily against the Adenovirus Hexon Protein

    Authors: , , , , , , , , , , , , , , , , , - The Journal of Immunology 2005 cited by 363

  16. International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jaap Goudsmit - Vaccine 2011 cited by 307

  17. Recombinant Adenovirus Serotype 26 (Ad26) and Ad35 Vaccine Vectors Bypass Immunity to Ad5 and Protect Nonhuman Primates against Ebolavirus Challenge

    Authors: , , , , , , , , , , , , , , , , , - Journal of Virology 2011 cited by 224

  18. A common solution to group 2 influenza virus neutralization

    Authors: , , , , , , , , , , , , , , , , , , , , , , - National Academy of Sciences, Proceedings of the National Academy of Sciences 2013 cited by 191

  19. Replication-Deficient Human Adenovirus Type 35 Vectors for Gene Transfer and Vaccination: Efficient Human Cell Infection and Bypass of Preexisting Adenovirus Immunity

    Authors: , , , , , , , , , , , , , , , , , , , , , , - Journal of Virology 2003 cited by 471

  20. Immunogenicity of Recombinant Adenovirus Serotype 35 Vaccine in the Presence of Pre-Existing Anti-Ad5 Immunity

    Authors: , , , , , , , , , , , , , , , , , - The Journal of Immunology 2004 cited by 384

  21. Mechanisms of Hemagglutinin Targeted Influenza Virus Neutralization

    Authors: , , , , , , , , , , , , - PLoS ONE 2013 cited by 172

  22. First-in-Human Evaluation of the Safety and Immunogenicity of a Recombinant Adenovirus Serotype 26 HIV-1 Env Vaccine (IPCAVD 001)

    Authors: , , , , , , , , , , , , , , , , , , , , , , - The Journal of Infectious Diseases 2012 cited by 168

  23. Novel Replication-Incompetent Vector Derived from Adenovirus Type 11 (Ad11) for Vaccination and Gene Therapy: Low Seroprevalence and Non-Cross-Reactivity with Ad5

    Authors: , , , , , , , , , , , , , , , , , - Journal of Virology 2004 cited by 143

  24. Immuno-activation with anti-CD3 and recombinant human IL-2 in HIV-1-infected patients on potent antiretroviral therapy

    Authors: , , , , , , , , , , , , , - AIDS 1999 cited by 240